Advanced Wound Management Market Analysis With BSN Medical, Ethicon Inc., Medline Industries, Inc. & Smith & Nephew PLC, 2022-2031

Growing investments in the healthcare sector, coupled with innovations in advanced wound management products are anticipated to positively shape demand in the upcoming years.

With increasing incidence of chronic wounds globally, Future Market Insights (FMI) projects the advanced wound management market to exceed US$ 6.5 Bn between 2021-2031.

Click to get Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-8422

In 2020, the unprecedented COVID-19 outbreak dampened sales in the advanced wound management market. However, with recovery of research and development initiatives focusing on solutions for optimal wound care, demand in the advanced wound management market will rise at a steady pace during the assessment period.

Incorporation of biomaterials such as alginates and silver in topical wound healing treatments will further drive sales. These developments are encouraging key market players to innovate effective advanced wound healing solutions.

Product developments in advanced wound dressing segment such as hydrogels, collagen, and hydrocolloids are on cards. Apart from these products, emergence of negative pressure wound therapy devices will boost sales in the market.

Besides this, government-backed initiatives such as public health insurance schemes in counties including the U.S., the U.K., and China will create lucrative growth opportunities in the advanced wound management market.

Key Takeaways from the Advanced Wound Management Market Analysis

  • Advanced wound dressing is anticipated to dominate the product segment.
  • Based on application, chronic ulcers will witness increasing adoption of advanced wound management.
  • Hospitals, followed by clinics are expected to account for maximum market sales.
  • The U.S. is projected to witness high demand in the advanced wound management market, owing to increasing number of diabetic patients in the country.
  • The U.K. will emerge as a lucrative market with rapid product developments by leading players.
  • China will exhibit high demand for advanced wound management due to increasing incidence of chronic wounds and reimbursements for medical expenditure.
  • Advanced wound management market in India is expected to grow at a steady pace, owing to growing cases of road accidents and chronic wounds.

“Increasing research and development activities aimed at offering advanced wound healing devices and fast-track approvals for novel advanced wound management products are anticipated to propel sales in the market through 2031,” says the FMI analyst.

Competitive Landscape

As per FMI’s analysis, ConvaTec Group Plc. Coloplast A/S, Molnlycke Health Care AB, 3M Healthcare, and Smith & Nephew PLC. are among the leading players in the market, accounting for approximately 3/4th of the market share.

Key players operating in the advanced wound management market are actively focusing on product innovations, strategic collaboration, mergers, acquisitions, and government approvals as a part of their growth strategies. For instance:

  • In July 2021, Ethicon Inc., a part of the Johnson & Johnson Medical Devices Company, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for the company’s transbronchial microwave ablation technology. The advanced technology uses robotic-assisted bronchoscopy for the treatment of debilitating diseases and conditions.
  • In July 2021, Illinois-based Medline Industries announced its plan to open a new distribution center worth US$ 100 Mn in the Katy area. The new distribution facility will bring the company’s total employee strength to around 375 employees.

More Insights into the Advanced Wound Management Market Report

In its latest report, FMI offers an unbiased analysis of the global advanced wound management market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (advanced wound dressing, wound contact layers, superabsorbent dressings, and negative pressure wound therapy devices), application type (chronic ulcers and non-healing surgical wounds) end-user type (hospitals, clinics, ambulatory surgical centers, and skilled nursing facilities) and across seven regions (North America, Latin America, Eastern Europe, Western Europe, Asia Pacific excluding Japan (APEJ), Japan, and Middle East & Africa).

Click to get the in-depth TOC of this Report: https://www.futuremarketinsights.com/reports/advanced-wound-management-market/table-of-content

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
​United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Pneumococcal Vaccines Market Overview & Analysis by Product Type: Pneumococcal Polysaccharide Vaccines, Pneumococcal Conjugate Vaccines-Forecast to 2022-2031

As per a study by Future Market Insights (FMI), the global pneumococcal vaccines market is expected to surpass a valuation of US$ 10124.9 million by 2021, expanding at a value-based CAGR of 7.37% during the forecast period 2021 to 2031.

Increasing incidence of pneumococcal diseases such as pneumonia, meningitis, and bacteremia is driving the market growth. According to a report published by Centers of Disease Control and Prevention in 2018, over 150,000 people in the U.S. are required emergency medical assistance due to pneumonia and approximately 3,500 deaths are reported in the country because of bacteremia and meningitis.

Ask for the Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-7078

Kids under the age of 5 years and adult over 65 years of age a more vulnerable to pneumococcal diseases. Pneumococcal vaccines plays a significant role in safeguarding people and also assist in the treatment of these diseases. Thus, the demand to curb the rising incidence of pneumonia is expected to create lucrative growth opportunities for the market.

Government and various organization such as UNICEF, the WHO, and others across the globe are taking initiatives to spread the awareness and reduce the burden of pneumococcal diseases. Attributed to this, the public health agencies is expected to remain the dominant the distribution channel segment over the next ten years.

Key Takeaways from FMI’s Pneumococcal Vaccines Market Study

  • The U.S. is anticipated to dominate the North America market on the back of high prevalence of pneumococcal diseases
  • The market in the U.K. is likely to grow at a steady pace, owing to the presence of leading market player in the country.
  • India will emerge as a highly lucrative market favored by the increasing number of government initiatives to curb the prevalence of pneumococcal diseases
  • Due to large pool of coronavirus and number of medical institutes and hospitals in China, the market in the country is likely to project rapid growth.
  • Based on product type, pneumococcal conjugate vaccines is estimated to lead the segment, supported by the increasing number of children vaccination programs.

“Several healthcare institutes, research centers, and leading manufacturers are focusing on research and development (R&D) and clinical trials for developing novel pneumococcal drugs to address the demand for vaccines for multiple serotypes. Their efforts are estimated to bode well for the market, spurring the sales,” says the FMI analyst.

Competitive Landscape

Leading players operating in the pneumococcal vaccines landscape are increasingly investing in research and development and conducting clinical trial for developing novel pneumococcal drugs. Besides this, some of the market players are focusing on receiving approvals from regulatory bodies to launch the products. For instance,

In January 2021, Pfizer Inc,, one of the leading pharmaceutical company, announced receiving an approval from the U.S. Food and Drug Administration (FDA) for its new drug named, PREVNAR 20. It is a pneumococcal conjugate vaccines for prevention of invasive disease and pneumonia caused by 20 pnemococcus stereotypes in adults aged 18 years or older.

In December 2020, Serum Institute of India announced receiving an regulatory approval for it’s new vaccine, PNEUMOSIL® India’s first developed pneumococcal vaccine, from World Health Organization.

More Insights on the Global Pneumococcal Vaccines Market

In its new offering, Future Market Insights, offers detailed segmentation on global pneumococcal vaccines market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is classified on the basis of product type (pneumococcal polysaccharide vaccines, pneumococcal conjugate vaccines), and distribution channel (pharmacies, community clinics, public health agencies, and others), across major regions (North America, Eastern Europe, Asia Pacific excluding Japan, Middle East & Africa, and Japan).

Ask for the TOC of this Report with figures: https://www.futuremarketinsights.com/reports/pneumococcal-vaccines-market/table-of-content

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
​United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Opioid Analgesics Market is Slated to Increase at a 5.4% CAGR in the Time Period of 2021-2031

According to a recent study by Future Market Insights (FMI), the global opioid analgesics market is projected to reach US$ 38.97 Bn in 2021, expanding at a 5.4% CAGR over the forecast period.

Opioids are a type of narcotic pain medication used to treat moderate to severe pain, such as diarrhea suppression, cough suppression, anesthesia, cancer pain, injury or trauma, surgical pain, and neuropathic pain.

Request for the Comprehensive Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-14043

Increasing incidence of chronic conditions such as cancer and chronic pulmonary obstructive disease (COPD) in the geriatric population is spurring demand for opioid analgesics. Opioids effectively help in post-operative pain management and pain caused by orthopedic disorders, resulting in high demand for the same.

As per the American Cancer Society, the global incidence of cancer was 19.3 million in 2020. According to the National Cancer Institute, 20% to 50% of cancer patients suffer from pain continuous pain.

Around 80% of patients suffering from advanced-stage cancer have severe pain. By 2030, the global burden of cancer is expected to grow to 21.7 million new cancer cases, majorly because of the growing aging population. As a result, sales of opioid analgesics are projected to rise in tandem.

Opioid analgesics are effective in relieving pain; however, excess consumption of opioids can result in mental and physical dependency. In response to this, manufacturers are investing in research and development to launch non-addictive opioid variants.

Key Takeaways:

  • Based on drug class, the oxycodone segment is expected to hold a market share of 19.7% in 2020.
  • In terms of indication, the surgical pain segment is projected to hold 45.5% of the total opioid analgesics market share.
  • The oral route of administration segment is expected to expand at a 6.5% CAGR through 2031.
  • Sales of opioid analgesics through hospital pharmacies are projected to generate revenues worth Us$ 23,355.2 Mn by 2031.
  • The U.S. is projected to lead the North America opioid analgesics market, capturing 86% of the total market share in 2021.
  • Germany will emerge as a lucrative market with sales growing at a 3.8% CAGR in 2021.
  • The U.K. is projected to lead the Europe opioid analgesics market, expanding at a 4.7% CAGR through 2031.
  • China is anticipated to account for 54.2% of the East Asia opioid analgesics market share in 2021.
  • Sales of opioid analgesics in India are expected to account for 35.4% of the South Asia market share in 2021.
  • Japan opioid analgesics market is projected to expand at a 5.6% CAGR, and South Korea will account for 14.5% of the East Asia market share.

“Increasing adoption of opioid maintenance treatment (OMT) to treat opioid dependence (OD), along with availability of opioid medications through online retail channels will continue providing tailwinds to opioid analgesics sales,” says an FMI analyst.

Competitive Landscape

Leading companies operating in the global opioid analgesics market are investing in research and development to launch commercially available and non-addictive opioids in the market to gain a competitive edge. Apart from this, mergers, acquisitions, and collaborations will remain a part of prominent growth strategies used by market players. Fos instance:

  • In September 2018, Novartis, an international healthcare organization, signed an agreement for the marketing, sales, and distribution of well-known pain medicine brands Voltaren (diclofenac sodium) and Cataflam (diclofenac potassium) in Malaysia, Thailand, and the Philippines.

More Insights into Opioid Analgesics Market Report

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global opioid analgesics market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on opioid analgesics segment based on drug class (morphine, codeine, fentanyl, meperidine, methadone, tramadol, oxycodone, dextromethorphan, buprenorphine and others), indication (surgical pain, cancer pain, neuropathic pain and other), route of administration (oral, parenteral, transdermal and other) distribution channel (hospitals, retail pharmacies, drug stores and online pharmacies) and across seven major regions.

Request for the complete TOC of tis Report: https://www.futuremarketinsights.com/reports/opioid-analgesics-market/table-of-content

About the Healthcare Division at Future Market Insights

Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
​United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Western Blotting Processors Market enabling it to surpass US$ 383.7 Million in valuation by 2031

Conventional western blotting processors are relatively inconsistent in terms of the efficiency of detecting protein traces in samples.

 While the technique of western blotting demands time and technical expertise, automation has magnified the process of throughput screening in western blotting, thereby facilitating increasing number of trials and accelerating the experimentation process.

Automated western blotting techniques enable the analysis of several samples at one go, with the only manual task being loading of the sample into the western blotting system.

Automation is currently trending the western blotting processors market, as revealed in a comprehensive research study by Future Market Insights

From an estimated valuation of US$ 235.5 Mn in 2021, the western blotting processors market is projected to reach a market value of just under US$ 329 Mn towards the close of 2031, exhibiting a decadal CAGR of 11.5%, according to the research report by Future Market Insights.

Manufacturers are Accelerating Product Launches and Eyeing Offshoring as a Viable Growth StrategyThe market for western blotting processors is highly competitive with the top companies accounting for a larger part of global sales. Leading companies are acquiring smaller companies and expanding their production capacities to gain a larger share of the global market.

Companies in the western blotting processors market are leveraging the available market opportunities to launch their products in full gear in the global market. One of the market companies leveraged an unexploited demand for point-of-care HIV diagnostics as its key entry strategy in the western blotting processors market.

Product registration followed by commercialisation is accelerating the product launch process and creating healthy competition in the global market for western blotting processors.

Manufacturers of western blotting processors are setting up production facilities in other countries so as to benefit from access to cheap labour and resource expertise, and realign their distribution and customer oriented strategies.

Another key player in the western blotting processors market recently made a strategic investment in the offshore development of its life sciences facility with a mandate to engage in the manufacturing and distribution of molecular biology products to a global clientele.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7365

Increasing Cases of HIV Enabling Western Blotting Processors Market GrowthThe number of HIV cases across the world is increasing by the day, causing a burden on the global healthcare industry. Monitoring and controlling the HIV epidemic depends on early detection of anti-HIV antibodies in human blood.

Western blot is a confirmed test that can detect anti-HIV antibodies in blood serum samples. This is one of the factors leading to an increase in the adoption of western blotting processors.

Proteomics is extensively used in the pharmaceuticals industry to identify specific proteins associated with particular diseases, with western blotting finding application in new drug discovery. In the field of medical diagnostics, proteomics is used in the diagnosis of biomarkers that are essentially proteins present in body fluids.

Western blotting helps in quick diagnosis of diseases by identifying proteins that are produced when the human body contracts a disease. Besides the healthcare and pharmaceuticals industry, western blotting also finds application in the agriculture sector to establish protein characterisation in seed quality testing; and in the food and beverages industry to detect whey milk protein in commercial grade soy milk to check for possible adulteration.

Western Blotting Processors Market Growth Challenged by High Costs, Low Innovation, and Unreliability of Automated DevicesAdvanced automated western blotting devices such as the high performance western blotting transfer system are highly priced than their traditional counterparts, thereby restricting adoption across several developing economies.

High cost of labour is another challenge in certain regions that continue to carry out protein tests using cheap traditional western blotting processors, thereby leading to time-consuming and high labour cost-inducing processes.

Then again, the global western blotting processors market has not witnessed notable innovation, with very few advanced products launched in recent years.

Further, results obtained from the western blotting process are not fully reliable or consistent and the devices need to be updated regularly to produce more efficient and reliable results. The aforementioned factors are challenging revenue growth of the global western blotting processors market.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7365

Market SegmentationBy Product Type:

  • Automated Dry Blotting Systems
  • Semi-Dry Blotting Systems
  • Traditional Wet Transfer Blotting Systems

By Application:

  • Agricultural Application
  • Food & Beverages
  • Medical Diagnostics
  • Scientific Research
  • Other Applications

By End Users:

  • Diagnostic laboratories
  • Pharmaceutical and Biotechnology Companies
  • Research & Academic institution
  • Others

By Regions:

  •  North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Western Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Benelux
    • Nordic
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • Rest of Eastern Europe
  • Asia Pacific excluding China & Japan
    • India
    • Australia & New Zealand
    • ASEAN
    • Rest of Asia- Pacific excluding China & Japan
  • Japan
  • China
  • MEA
    • GCC Countries
    • South Africa
    • Rest of MEA

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-7365

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

Biopsy Device Market is expected to reach US$ 3089.2 Million by the end of 2031

Over the 10-year forecast period 2021-2031, the global biopsy device market is estimated to witness a moderate yet promising CAGR of 5.2%, according to Future Market Insights. In a recently published report titled “Global Biopsy Device Market: Global Industry Analysis and Opportunity Assessment, 2021–2031” Future Market Insights analyses the market for biopsy device and offers key insights factors driving growth. Valued at around US$ 1,862.6 Mn in 2021, the market is forecast to surpass a valuation of US$ 3,089.2 Mn by 2031-end.

Patients are increasingly preferring minimally invasive surgical procedures in order to avoid conventional surgical complications and side-effects, promoting sales of biopsy devices, leading to the growth of the biopsy devices globally. In addition to enabling the accurate diagnosis, a biopsy device assures minimal patient discomfort and trauma. This is identified to be a major factor impacting the popularity of biopsy, and biopsy device thereby.

Key Opportunities for Manufacturers and Suppliers:

  • Developing economies present lucrative, untapped markets for biopsy device.
  • Growing adoption of hybrid imaging technology will underpin new growth opportunities.
  • Following massive consumption by hospitals, demand for biopsy device from specific oncology centers and research institutes will prompt at multiple opportunities in near future.
  • Surging demand for minimal invasive breast biopsy highlights lucrative opportunities that lie in the breast cancer sector.
  • Increasing adoption of biopsy device by oncologists will generate several revenue generation opportunities in the disease monitoring sector.

Supported by increasing discretionary funding for cancer research, growing government expenditure for healthcare and favorable reimbursement scenario (especially in the U.S.) will collectively elevate the revenue sales of the global biopsy device market. Collaborations between various government and private companies, fuelled by increasing awareness about disease diagnosis and monitoring, will further elevate the market growth in near future.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1192

M&A and Technological Upgrades Remain at the ForefrontA majority of key players in the global biopsy device market are currently focusing on providing innovative biopsy tests and technological upgrades. Mergers, acquisitions, and partnerships with diagnostic laboratories will help to strengthen their presence in the global market.

Among the top companies, Becton, Dickinson and Company is concentrating on innovative, cost-effective product development, whereas Hologic, Inc. is targeting manufacture and sales of biopsy devices, especially for breast cancer surgeries. Other notable players include Boston Scientific Inc., C. R. Bard, Inc., B. Braun Melsungen AG, Cook Medical, INRAD Inc., and PLANMED OY.

Argon Medical, one of the promising new entrants, is expanding its product portfolio and collaborating with established players, whereas for Devicor Medical Products Inc., M&A remains the key strategy.

North America Remains the Most Lucrative MarketNorth America will remain the dominant market and is expected to surpass US$ 882 Mn by 2031 end, accounting for over 33% share of the market. Western Europe is expected to remain the second largest market for biopsy device, crossing a value of US$ 683 Mn by the end of 2031, capturing over 26% share of the market.

APEJ, with around 14% market value share in 2031, reaching a valuation of around US$ 370.0 Mn by the end of forecast period. MEA will register the fastest CAGR of 7.3%, followed by APEJ and Latin America with the respective CAGRs of 7.1% and 6.5% over 2021-2031. North America, Europe, and Japan will see moderate growth over the forecast period.

Biopsy Needles To Remain Top-selling Product CategoryBy product type, needles will remain dominant with over 36% share of the market value in 2031, whereas guns will represent the second largest sub-segment with over 26% market value share in 2031. With growing significance of early diagnosis of breast biopsy, guidance system segment is estimated to gain around 222 BPS in its market share by 2031 over 2021. Stereostatic X-ray guided biopsy will drive the guidance system segment through to 2031. Reagents and kits will witness moderate consumption.

Medical Diagnostics Monopolize Application SegmentBased on application type, medical diagnostics will continue to hold a dominant share of over 61% by 2031 end, in terms of revenues. Scientific research, accounting for the rest, will witness an impressively growing CAGR of 6.9% over 2021-2031. This segment is expected to reach beyond US$ 1,008.0 Mn in 2031.

Hospitals Remain Largest End-use ConsumerBy end-user, hospitals will continue to contribute nearly 50% share to the market value by 2031 end. This end-use segment will witness a robust CAGR of 8.2%. Diagnostic centres will account for over 23% in 2031 with a slight decline over 2021-2031, whereas specialised oncology centres are anticipated to expand at a CAGR of 6.1% during 2021-2031.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1192

Biopsy Device Market – Market SegmentationBy Product Type:

  • Guidance System
    • Stereotactic X-Ray Guided Biopsy
    • Ultrasound Guided Biopsy
    • MRI Guided Biopsy
  • Needles
    • Core Needles
    • Fine Aspiration Needles
  • Guns
  • Reagents and Kits
  • Others (Brushes, Curettes and Punches etc.)

By Application:

  • Medical Diagnosis
  • Scientific Research

By End Use:

  • Hospital
  • Specialised Oncology Centres
  • Diagnostic Centres
  • Research Institutes

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • MEA

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/1192

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

Sleep Apnea Diagnostic Systems Market valuation to reach US$ 5.4 Billion over the forecast period of 2021 and 2031.

Future Market Insights, Dubai: ESOMAR-certified consulting firm Future Market Insights’ projects the global sleep apnea diagnostic systems market valuation to reach US$ 5.4 Bn over the forecast period of 2021 and 2031.

Growing demand for advanced polysomnography (PSG) devices within sleep centers & clinics and hospitals is accelerating sleep apnea diagnostic systems sales across the globe.

Demand for sleep apnea diagnostic systems is rising extensively in emerging economies as there is a large pool of undiagnosed and untreated sleep apnea patients.

Increasing application within sleep centers & clinics and at homecare settings for in-lab testing is expected to spur the sales during the assessment period.

As per the FMI’s analysis, due to the outbreak of COVID-19, the global sleep apnea diagnostic systems market registered spike in demand as the number of patients with depression and mental health issues spurred during 2020-2021.

Increasing funding by governments and initiatives undertaken to create awareness about sleep disorders have encouraged manufacturers to increase the research & development activities. This also has encouraged the development of advanced PSG devices and wearable sleep apnea diagnostic systems.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-777

Key Takeaways from FMI’s Sleep apnea diagnostic systems Market Study

  • By end-user, sleep centers and clinics are expected to be the primary end-user in sleep apnea diagnostic systems market
  • Hospitals and homecare settings are expected to exhibit robust growth during the forecast period owing to the increasing demand for devices at home-care settings
  • In terms of product, polysomnography (PSG) devices are expected to be the most preferred devices
  • The U.S. will be the most lucrative market owing to the rising prevalence of sleep apnea and other lifestyle disorders
  • China and India will spearhead the growth of East & South Asia backed by the adoption of advanced PSG devices across the region
  • Brazil is expected to have incremental growth opportunities owing to the large pool of untreated and undiagnosed cases of sleep apnea

“Ever expanding pool of undiagnosed sleep apnea patients, especially across developing economies such as India, China, and Brazil, will generate remunerative growth opportunities for the sleep apnea diagnostic systems market players over the coming years,” says the FMI analyst. 

Who is Winning?Koninklijke Philips N.V., Becton, Dickinson, and Company, Braeden Medical Corporation, Advanced Brain Monitoring Inc., SOMNO medics GmbH, ResMed Inc., BMC Medical Co. Ltd., Natus Medical Incorporated, MGC Diagnostic Corporation, and Cleveland Medical Devices Inc. among others are some prominent players operating in the Sleep apnea diagnostic systems market.

As per the FMI’s analysis, Koninklijke Philips N.V., and ResMed Inc. are identified as leading players in the sleep apnea diagnostic systems market. These manufacturers are focusing on product innovation and new launches to maintain their leading position.

Collaborations with hospitals and sleep centers & clinics is the core strategy to strengthen their distribution networks. Key players are also focusing on other strategies such as mergers and product introductions to increase their sales.

Other regional and local players also account for considerable market share in the global sleep apnea diagnostic systems market, opines Future Market Insights.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-777

Get More Insights on Global Sleep Apnea Diagnostic Systems MarketIn its latest report, FMI provides an incisive coverage on the global sleep apnea diagnostic systems market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (polysomnography (PSG) devices, sleep apnea screening devices, and actigraphy monitoring devices), end-user (home care settings, hospitals, and sleep centers & clinics), and across major regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Sleep Apnea Diagnostic Systems Market by CategoryBy Product:

  • Polysomnography (PSG) Devices
    • Ambulatory PSG Monitoring Devices
    • Clinical PSG Monitoring Devices
    • Sleep Apnea Screening Device
  • Nasal Flow Sensors
  • Peripheral Capillary Oxygen Saturation (SPO2)
  • Actigraphy Monitoring Devices

By End-User Type:

  • Home Care Settings
  • Hospitals
  • Sleep Centers & Clinics

By Region:        

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East and Africa (MEA)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-777

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

High Flow Oxygen Therapy Devices Market is expected to reach US$ 1.4 Billion by 2031

[250 Pages Report] The rising prevalence of acute respiratory failures (ARF) due to the COVID-19 outbreak, risk of community infection, increasing demand for high flow nasal cannula, and advancements in high Flow Oxygen Therapy Devices are some key factors contributing to the growth of the high flow oxygen therapy devices market.

According to a recent study by Future Market Insights (FMI), these factors have proven crucial at enabling growth in the high flow oxygen therapy devices market. Sales of high flow oxygen therapy devices are expected to top US$ 1.7 Bn in 2021, at a CAGR of -6.4% during 2021-2025 and CAGR of 1.4% during the forecast period (2025-2031).

Public health issues worldwide, including Acute Respiratory Failure (ARF), pneumonia, asthma, and interstitial lung disease, pose a significant socioeconomic burden on individuals and societies.

Presently, COVID-19 is the primary risk factor for ARF. COVID-19 symptoms such as low blood-oxygen level and pneumonia in patients increase the risk of ARFs. Because of the growing ageing population and increased exposure to risk factors, ARF and pneumonia are becoming more prominent problems across the world, which is fuelling the demand for high flow oxygen therapy devices.

The World Health Organization (WHO) Child Health Epidemiology Reference Group estimates that the pneumonia resulted 105.7 million new cases in 2017; of these 13% were severe and needed immediate hospitalization.

Consistent rise in incidence of pneumonia will fuel the demand for high floe oxygen therapy devices through the forecast period. Indoor air pollution was a major risk factor that was estimated to have led to 29% of pneumonia deaths in 2017.

Outdoor air pollution was responsible for another 18% of all deaths. In addition, an increase of 81.1% in the number of pneumoconiosis cases were observed for both sexes from 1990 to 2017 worldwide. Thus, the growing burden of respiratory diseases along with the outbreak of COVID-19 across the world is expected to drive the high flow oxygen therapy devices market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13794

Key Takeaways from High Flow Oxygen Therapy Devices Market Study

  • Demand for heated humidifiers is expected to grow at -6.6% CAGR during 2021-2025 and 1.3% CAGR through 2025-2031, owing to the occurrence of the COVID-19 pandemic.
  • The acute respiratory failure segment accounted for a higher share of 90% among applications. This can be due to the rising COVID-19 cases that lead to acute respiratory failure in the infected patients and require non-invasive respiratory support.
  • 500 Beds and Above Hospitals are projected to capture over 51% of the global market by 2031. This is attributed to the growing burden of respiratory diseases.
  • North America is the largest revenue-generating region for high flow oxygen therapy devices, with the U.S. accounting for nearly 96% of the regional market in 2031.
  • South Asia is the second most lucrative market with India accounting for over 58% of the share in 2031.
  • Japan holds the leading position in East Asia and is expected to account for over 42% of the market in 2031.

 “Increasing funding for R&D activities aimed launching novel products and solutions and healthcare recognition and recommendation of high-flow nasal cannula oxygen therapy will continue creating growth opportunities for manufacturers through the assessment period, ending in 2031,” says the FMI analyst

Who is winning?

Some of the leading manufacturers of high flow oxygen therapy devices are focusing on product approvals and launch strategies for global expansion objectives, thereby, enhancing their market presence. The leading key players are also focusing on innovation and launching new technologies for increasing the efficiency of products.

  • In June 2020, Armstrong Medical introduced the second generation FD140i, an improved dual therapy flow driver with an easier transition from CPAP to HFOT.
  • In 2019, TherOx Company received approval for SuperSaturated Oxygen Therapy system from the U.S. Food and Drug Administration (FDA) to be one of the effective therapies for cardiovascular diseases.

The key market players covered by FMI include Draegerwerk AG & Co. KGaA, Teleflex Medical GmBH, Philips Respironics, Vapotherm, Inc., ResMed, Vyaire Medical, Inc., Fisher & Paykel Corporation Ltd., Armstrong Medical, Flexicare Medical, Hamilton Medical Inc., Intersurgical Inc., Inspired Medical, WILAMed GmBH, Besmed Health Business Corp, Shenzhen Micomme Medical Technology Development Co., Ltd, Shenyang RMS Medical Tech Co. Ltd. and BMC Medical Co., Ltd.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13794

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global high flow oxygen therapy devices market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on high flow oxygen therapy devices segment based on the product (High Flow Nasal Cannulas, High Flow Oxygen Masks, Breathing Circuits, Heated Humidifiers and Accessories) Application (Pneumonia and Acute Respiratory Failure) End User (Less than 100 Beds Hospitals, 100-250 Beds Hospitals, 250-500 Beds Hospitals and 500 Beds and Above Hospitals) across seven major regions.

High Flow Oxygen Therapy Devices Market by CategoryProduct:

  • High Flow Nasal Cannulas
  • High Flow Oxygen Masks
  • Breathing Circuits
  • Heated Humidifiers
  • Accessories

Application:

  • Pneumonia
  • Acute Respiratory Failure

End-User:

  • Less than 100 Beds Hospitals
  • 100-250 Beds Hospitals
  • 250-500 Beds Hospitals
  • 500 Beds and Above Hospitals

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-13794

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

Cardiac Ultrasound Systems Market is forecast to register 5% CAGR between 2021 and 2031, as per Future Market Insights (FMI).

The cardiac ultrasound systems market exhibited year-on-year growth of 5.9% in 2021, backed by introduction of mobile connectivity in handheld wireless cardiac ultrasound systems and growing preference for real-time imaging solutions among patients. Future Market Insights (FMI) states that cardiac ultrasound systems market revenue grew by 6% between 2016 and 2020. It is predicted that sales will increase at a CAGR of 5.0% between 2021 and 2031.

Growing preference for connected ultrasound systems for real-time diagnosis among patients marks a recent milestone, shaping the performance of cardiac ultrasound systems landscape.

The World Health Organization (WHO) reports that more than 17 million people die from cardiovascular disorders globally each year. Rise in referrals to cardiologists due to complications and rapid technological advancements to make the existing cardiac ultrasound devices more compact and user-friendly will positively influence the market growth throughout the forecast period.

The global cardiac ultrasound systems landscape is slated for positive growth prospects in the near future due to increasing efforts to develop stronger distribution channel and manufacturers switching to emerging countries to attain high return of investments.

Surge in number of specializations in imaging and radiological technology along with dramatically growing number of independent imaging centers will provide impetus to revenue growth in upcoming years.

Portable cardiac ultrasound systems are expected to exhibit remarkable market penetration in recent years, due to growing popularity of bedside ultrasonography among people.

Lack of favorable reimbursement and insurance policies along with high cost of equipment are impeding the sales of cardiac ultrasound systems, especially in developing economies.

Lack of adequate grants from government and requirement of high capital investments for installation of modern cardiac ultrasound systems will further hinder the market growth.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-7692

Key Takeaways from FMI’s Cardiac ultrasound systems Market Study

  • North America cardiac ultrasound systems market will exhibit steady growth at 4.70% CAGR through 2031, driven by increasing demand for portable and attractive cardiac devices among cardiologists in U.S. and Canada.
  • European cardiac ultrasound systems market led by Germany, France, and Italy is forecast to grow at 5.30% CAGR during the forecast period. Rise in growth can be attributed to increasing government spending on healthcare and presence of top manufacturers in the region.
  • Increasing cases of cardiovascular and lifestyle diseases in India will drive the demand for cardiac ultrasound systems in the country.
  • In 2021, Japan and South Korea are estimated to account for 20% and less than 4% share respectively of the Asia Pacific cardiac ultrasound system market. Rising geriatric population and increasing popularity of online sales are key growth drivers in these countries.
  • By product type, hand-held ultrasound systems sales are projected to surpass the market valuation of US$ 2,300 Mn at a CAGR of 6.5% in 2021. Integration of 4D imaging technology and internet of things (IoT) will drive the market growth of this segment.

“Continuous development to increase efficiency of healthcare devices will influence the demand for cardiac ultrasound systems across the globe. Increasing demand for lightweight and portable cardiac ultrasound systems from mobile clinics will boost the market in the upcoming years,” says the FMI analyst.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-7692

Who is Winning?

Future Market Insights presents analysis on the key trends affecting the cardiac ultrasound systems market and discusses the strategies adopted by market players to strengthen their position. It estimated that the cardiac ultrasound systems market is dominated by GE Company, Fujifilm, Holdings Corporation, Siemens AG, Koninklijke Philips N.V., Toshiba Medical System Corp., Hitachi Medical Corp., and Esaote SpA as they hold majority of market share in 2021.

Leading market players are focusing on strategic merger, acquisitions, and partnerships to expand their product portfolio. Smaller players are concentrating on strengthening their value chain to gain significant market share, says FMI.

In order to cater growing the patient pool with cardiovascular diseases and high demand for non invasive diagnostics, manufacturers are focusing on new product development.

In 2020, Siemens Healthineers India launched new ACUSON redwood ultrasound system at Gandhinagar. This advanced system precisely detects lesions and characteristics. It is installed with artificial intelligence (AI) powered tools to reduce the exam burden and improve efficiency.

In 2018, Philips introduced new cardiac ultrasound solutions “EPIQ CVx” equipped with anatomical intelligence which offers customized applications for diagnostic, pediatric and interventional echocardiography. EPIQ CVx has faster data processing, high quality imaging, and automated quantification and tailored exam tools developed to assist cardiologists in delivering better care.

Prominent players operating in the cardiac ultrasound systems market are:-

  • Hitachi, Ltd.
  • Analogic Corporation
  • Toshiba Corporation
  • Esaote SpA
  • Samsung Medison Co. Ltd
  • FUJIFILM Holdings Corporation
  • Mindray Medical International Ltd.
  • GE Healthcare

More Insights on the Cardiac ultrasound systems Market

In its latest report, FMI offers an unbiased analysis of the global cardiac ultrasound systems market, providing historical data for the period of 2018-2028 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of by product type (cart/trolley cardiac ultrasound devices and compact/handheld ultrasound scanners), by end use (hospitals and clinics, diagnostic imaging & surgical centers, ambulatory surgical centers, and others), and by region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa)

Key Segments Covered In Cardiac Ultrasound Systems Market Study:By Product:

  • Cardiac system
  • Ultrasound system
    • Cart/Trolley Cardiac Ultrasound Devices
    • Compact/Handheld Ultrasound Scanners

By End User:

  • Hospitals And Clinics
  • Diagnostic Imaging And Surgical Centers
  • Ambulatory Surgical Centers
  • Others

By Region:

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East and Africa (MEA)

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/7692

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

3D Printed Medical Devices Market is set to experience a significant growth rate of 16.1% CAGR from 2022 to 2028

[212 Pages Report] Currently heading towards a market value of over US$ 440 Mn, the global market for 3D printed medical devices is projected for stupendous growth at 16% CAGR during 2022- 2029. North America will remain the leading market for 3D printed medical device sales, whereas the market attractiveness of Asia Pacific has been rising notably.

The market growth is primarily assisted by advancements in 3D printing technology, surging government spending in healthcare sector, increasing usage of 3D printed medical devices for medical procedures, and relative simplification of the manufacturing process of 3D printed medical devices. Introduction of Computer-aided Design (CAD) for 3D printing can create trail ready devices, thereby reducing manufacturing time, time to market as well as operational cost.

Key Takeaways – 3D Printed Medical Devices Market Study

  • Although metals and alloys are most preferably used for 3D printed medical devices, biomaterial inks are expected to gain traction during the forecast period owing to their highly biocompatible and versatile physical properties.
  • PolyJet – InkJet 3D printing technology currently holds maximum share of 3D printed medical devices market. However, consistent development and adoption of innovative technologies may reduce the 3D printed medical devices market share of this technology during the forecast period.
  • Use of 3D printing technology in orthopedic implants is shaping the future of 3D printed medical devices market. It currently accounts for nearly half of the market value.
  • The consistently expanding patient pool and growing preference for personalized implants in joint replacement surgeries will remain key boosters to growth of 3D printed medical devices demand in orthopedics.

Asia Pacific has become the global hub of opportunities, and the leaders in 3D printed medical devices landscape have been eying the opportunity here – owing to the massive application scope, remarkably growing patient population, and relatively less manufacturing costs.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1501

Who Is Winning?

Until late 2016, the key focus of most leading players in the 3D printed medical devices market was geographic expansion through acquisition and merger. In May 2016, Johnson & Johnson announced collaboration with a subsidiary of HP Inc. for manufacturing personalized healthcare solutions at reduced costs through 3D printing techniques. J&J collaborated with Organovo to carry out feasibility study on bio printed human tissue for testing new medications to work with Carbon 3D, famous for ultra-fast Continuous Liquid Interface Production (CLIP) technology for production of custom surgical devices.

The focuse is now gradually shifting towards expansion through strategic partnerships to improve their distribution network. For instance, in 2017, Envision partnered with ScanSource, Inc. to deliver 3D printing solutions to resellers in the Americas. Similarly, in 2018, 3D Systems and Stryker announced distribution partnership for VSP (Virtual Surgical Planning) and anatomical models for carniomaxillofacial specialty.

Key Market Segments Covered in 3D Printed Medical Devices Industry ResearchBy Application :

  • Orthopaedic Implants
  • Dental Implants
  • Cranio-maxillofacial Implants
  • Internal and External Prostheses

By Technology :

  • Stereolithography (SLA) – Liquid Based 3D Printing
  • Selective Layer Sintering (SLS) – Powder Based 3D Printing
  • Digital Light Processing(DLP)
  • Fused Deposition Modeling (FDM): Plastic Filament Extrusion Based
  • PolyJet / InkJet 3D Printing
  • Electronic Beam Melting (EBM)

By Distribution Channel :

  • Hospitals
  • Ambulatory Surgical Centers
  • Diagnostic Centers

By Material :

  • Plastics
    • Thermoplastics
    • Photopolymers
  • Biomaterial Inks
    • Polymers
    • Ceramics
    • Hydrogels
  • Metals and Alloys

By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East & Africa

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1501

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

Clinical Oncology Next-generation Sequencing Market is projected to expand at a prolific CAGR of 16.3% between 2022 and 2029

[194 Pages Report] Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology is one of the important applications of next-generation sequencing. It is an advanced and faster method of sequencing. Clinical oncology next-generation sequencing includes kits & reagents, services, sequencing platforms, and sequencing products. The kits and reagents used for sequencing are expected to witness significant growth in the overall market.

North America is expected to be a prominent region in the global clinical oncology next-generation sequencing market owing to the presence of well-developed healthcare infrastructure and numerous technological advancements in the region. North America and Europe are expected to witness a significant growth rate in the clinical oncology next-generation sequencing market.

Synthesis Sequencing Technology to Hold a Major Market Value ShareBased on the technology, the clinical oncology next-generation sequencing market has been segmented into pyro sequencing, sequencing by synthesis (SBS), and Single-Molecule Real-Time Sequencing (SMRT), nanopore sequencing, ligation sequencing, and reversible dye termination sequencing. Synthesis sequencing is however expected to hold a significant share in the clinical oncology next-generation sequencing market. Ion semiconductor sequencing is a method of DNA sequencing in which hydrogen ions are detected based on the polymerisation of DNA. Pyro-sequencing includes identifying the order of nucleotides in DNA based on the “sequencing by synthesis” principle, in which the sequencing is performed with the help of DNA polymerase. SBS is a technique used to determine the series of base pairs in DNA, which is also known as DNA sequencing.

There are various applications associated with clinical oncology next-generation treatment market. They include whole tumor genome sequencing, whole tumour exome sequencing, targeted tumour genome profiling, tumour transcriptome sequencing, tumour-normal comparisons, and other applications. Targeted tumor genome profiling is expected to hold a large share of the clinical oncology next-generation treatment market. On the basis of end user, the clinical oncology next-generation sequencing market has been segmented into hospital laboratories, clinical research organisations, diagnostic laboratories, and others. Clinical research laboratories are expected to hold a large revenue share in the clinical oncology next-generation sequencing market.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9543

Apart from the factors driving the clinical oncology next-generation sequencing market, there are few factors that are likely to hinder the overall growth of the clinical oncology next-generation sequencing market, such as high costs associated with the establishment of sequencing platforms, low quality of outsourcing services, and inadequate availability of sequencing platforms in some regional markets. On the other hand, increasing biomedical research using clinical oncology, increasing government funding for life science projects, substantial decline in the prices of sequencing, and technological advancements in the field of sequencing are some of the major factors driving the growth of the clinical oncology next-generation sequencing market.

Tier 1 Companies Hold Nearly 3/5th Share of Global Market ValueThe report tracks some of the key companies operating in the clinical oncology next-generation sequencing market such as QIAGEN N.V., Thermo Fisher Scientific., Pacific Biosciences of California, Inc., F. Hoffmann-La Roche Ltd Oxford Nanopore Technologies, Ltd., Takara Bio, Inc., Illumina Inc., PerkinElmer Inc.and Agilent Technologies, Inc. Thermo Fischer Scientific, Oxford Nanopore Technologies Ltd., and Illumina are expected to hold a signficant share of the clinical oncology next-generation sequencing market. These first tier companies hold a share of approximately 60% in the clinical oncology next-generation sequencing market.

Clinical oncology next-generation sequencing Market by CategoryBy Component:

  • Sequencing Platforms
  • Sequencing Products
  • Kits and Reagents
  • Services

By Technology:

  • Ion Semiconductor Sequencing
  • Pyro-Sequencing
  • Synthesis Sequencing (SBS)
  • Real Time Sequencing (SMRT)
  • Ligation Sequencing
  • Reversible Dye Termination Sequencing
  • Nano-Pore Sequencing

By Application:

  • Whole Tumor Genome Sequencing
  • Whole Tumor Exome Sequencing
  • Targeted Tumor Genome Profiling
  • Tumor Transcriptome Sequencing
  • Tumor-normal Comparisons
  • Others

By End User:

  • Hospital Laboratories
  • Clinical Research Organizations
  • Diagnostic Laboratories
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-9543

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/